Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
^Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program
What sets retatrutide apart is its triple agonist approach, which means it acts on three hormone pathways in your body at the same time: GLP-1, GIP, and glucagon
That said, the side effect profile overlaps significantly with GLP-1 agonistsGI symptoms like nausea, vomiting, and diarrhea are still common, especially during dose escalation
For composite kidney outcomes, the HR was 0.52 (95% CI 0.330.83) with SGLT2is and 0.70 (95% CI 0.590.83) without SGLT2is ( P -value for interaction 0.38) (Table 3)
Het wordt momenteel bestudeerd vanwege de mogelijke effecten op receptor-gemedieerde signalering, moleculaire dynamiek en endocriene functies in preklinische onderzoeksmodellen
We specialize in personalized pharmaceutical care, offering compounding services and customized medications tailored to your unique needs
